Results 11 to 20 of about 303,717 (280)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +2 more sources

HSP70 inhibitors upregulate prostaglandin E1-induced synthesis of interleukin-6 in osteoblasts

PLoS ONE, 2022
Interleukin-6 (IL-6) is a pro-inflammatory and bone-resorptive cytokine that also regulates bone formation. We previously showed that prostaglandin E1 (PGE1) induces the synthesis of IL-6 by activating p44/p42 mitogen-activated protein kinase (MAPK ...
Gen Kuroyanagi, Junko Tachi, Kazuhiko Fujita, Tetsu Kawabata, Go Sakai, Daiki Nakashima, Woo Kim, Kumiko Tanabe, Rie Matsushima-Nishiwaki, Takanobu Otsuka, Hiroki Iida, Osamu Kozawa, Haruhiko Tokuda   +12 more
doaj   +5 more sources

Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors [PDF]

Neurology Neuroimmunology & Neuroinflammation, 2021
BACKGROUND AND OBJECTIVES: To describe the marked clinical and biological responses of a targeted treatment with anti-interleukin-6 (IL-6)-receptor antibody and Janus kinase (JAK) inhibitors in a patient with a severe, corticoresistant CNS toxicity of ...
Berzero G., Birzu C., Psimaras D., Hermine O., Kramkimel N., Zahr N., Picca A., Valyraki N.   +7 more
core   +4 more sources

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience

Современная ревматология, 2022
Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods.
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina   +8 more
doaj   +2 more sources

Interleukin-6 inhibitor : tocilizumab

, 2016
Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6.
Mahler, Stephen M., Pile, Kevin (R17082), Stephen M. Mahler, Garry G. Graham, Kevin D. Pile, Graham, Garry G.   +5 more
core   +6 more sources

Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6

Molecules
Human Interleukin-6 (hIL-6) is a pro inflammatory cytokine that binds to its receptor, IL-6Rα followed by binding to gp130 and subsequent dimerization to form a hexamer signaling complex.
Ankit Joshi, Zhousheng Xiao, Shreya Suman, Connor Cooper, Khanh Ha, James A. Carson, Leigh Darryl Quarles, Jeremy C. Smith, Madhulika Gupta   +8 more
doaj   +5 more sources

Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. [PDF]

J Clin Rheumatol, 2021
Abstract Rheumatoid arthritis (RA) is a multisystem disease that affects the joints and various organs, resulting in compromised quality of life and increased mortality. A wide spectrum of treatment options is available for RA. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are the first-line of treatment for RA ...
Yip RML, Yim CW.
europepmc   +4 more sources

Effect of Medicine on Interleukin-6 Inhibitors and their Forms Against COVID-19

Biointerface Research in Applied Chemistry, 1994
Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), previously known as the 2019 novel coronavirus (2019-nCoV). The first cases were seen in December 2019 in Wuhan.
Kusat, Kevser, Türker, Jülide, Akgol, Sinan   +2 more
core   +4 more sources

The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling [PDF]

Biochemical Journal, 2004
peer reviewedThe immediate early response of cells treated with IL-6 (interleukin-6) is the activation of the signal transducer and activator of transcription (STAT)3.
Akihiko YOSHIMURA, Sobota, Radoslaw M., Patrick FISCHER, Schmitz, Jochen, Johnston, James A., Radoslaw M. SOBOTA, Niemand, C., Yoshimura, Akihiko, Heinrich, Peter C., Lehmann, Ute, Jochen SCHMITZ, Lehmann, U., Yoshimura, A., Schmitz, J., Gerhard MÜLLER-NEWEN, Sobota, R. M., Serge HAAN, Iris BEHRMANN, Heinrich, P. C., Linnemann, S., BEHRMANN, Iris, Schaper, Fred, James A. JOHNSTON, Peter C. HEINRICH, Fischer, P., HAAN, Serge, Johnston, J. A., Ute LEHMANN, Schaper, F., Fred SCHAPER, Fischer, Patrick, Müller-Newen, Gerhard, Müller-Newen, G., Heinrich, Peter, Sonja LINNEMANN, Niemand, Claudia, Linnemann, Sonja, Sobota, Radoslaw Mikolaj, Claudia NIEMAND   +38 more
core   +5 more sources

The role of Interleukin 6 inhibitors in therapy of severe COVID-19. [PDF]

Biomed Pharmacother, 2020
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cytokines and chemokines, leading to pathologic activation
Nasonov E, Samsonov M.
europepmc   +4 more sources